Melanoma panel provides more tumor information
Answers from the Lab
Melanoma tumors vary greatly, complicating decisions about optimal patient care. In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive MayoComplete Melanoma Panel better informs prognosis and treatment.
"This updated version of the panel adds 12 genes associated with melanoma and uses whole exome sequencing. It will be very helpful for better classification of melanoma, which is critical for clinical treatment guidance," Dr. Guo says.
The assay can be applied to a wide variety of cases, including unusual tumors that aren't yet diagnosed as melanoma and complex melanomas whose molecular signatures can guide prognosis and treatment. "This new panel is for a broader population of patients and provides more informative molecular testing for melanoma," Dr. Guo says.
Microsatellite instability (MSI) status — an emerging predictive and prognostic biomarker for immunotherapy response in cancer — is included in the new assay. "The addition of MSI will definitely provide more clinical and molecular insight for the classification of melanoma, with the potential for MSI-targeted therapy in the future," Dr. Guo says.
Listen to learn more about Mayo Clinic Laboratories' updated MayoComplete Melanoma Panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
MCMLN | MayoComplete Melanoma Panel
This assay requires at least 20% tumor nuclei
For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4mm x 4mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3mm x 1mm x 10 slides: approximate/equivalent to 36mm(2).
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block
Additional Information: Unused unstained slides will not be returned
Collection Instructions: Submit 1 to 3 slides stained and cover slipped with a preferred total of 5000 nucleated cells, or a minimum of at least 3000 nucleated cells
Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times
Additional Information: Cytology slides will not be returned
Analytic time: 12 days
Days performed: Monday through Friday
Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it.
Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs diagnosis and treatment. The phenotype-based panel covers the complete list of neuromuscular genes and their variants.